JP2004002473A - プラバスタチンナトリウム錠 - Google Patents
プラバスタチンナトリウム錠 Download PDFInfo
- Publication number
- JP2004002473A JP2004002473A JP2003303781A JP2003303781A JP2004002473A JP 2004002473 A JP2004002473 A JP 2004002473A JP 2003303781 A JP2003303781 A JP 2003303781A JP 2003303781 A JP2003303781 A JP 2003303781A JP 2004002473 A JP2004002473 A JP 2004002473A
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- pravastatin sodium
- substance
- tablets
- magnesium aluminate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 title claims abstract description 20
- 229960001495 pravastatin sodium Drugs 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 7
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 6
- 238000007907 direct compression Methods 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract description 9
- 229930195725 Mannitol Natural products 0.000 abstract description 9
- 239000000594 mannitol Substances 0.000 abstract description 9
- 235000010355 mannitol Nutrition 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 9
- 150000002596 lactones Chemical class 0.000 abstract description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract description 4
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 229940069428 antacid Drugs 0.000 abstract description 2
- 239000003159 antacid agent Substances 0.000 abstract description 2
- 230000001458 anti-acid effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000010828 elution Methods 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000007514 bases Chemical class 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- -1 magnesium oxide Chemical class 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】 錠剤の賦形成分として中性ないしpH9未満である物質を用いてプラバスタチンナトリウム錠を常法によって製造する。緩衝作用または制酸作用ある物質を賦形成分の一部として用いるのが好ましい。またマンニトールをベースとし、直接法によって打錠して得た錠剤は、ラクトン体への変化を防止できるのみならず、崩壊時間および溶出時間が遅延しない。
【選択図】 なし
Description
処方例1(1錠あたり)
プラバスチンナトリウム 5mg
乳糖 64mg
リン酸水素カルシウム 15mg
カルボキシメチルセルロースカルシウム 5mg
ヒドロキシプロピルセルロース 2mg
ステアリン酸マグネシウム 1mg
計 92mg
プラバスチンナトリウム 5mg
乳糖 64mg
メタケイ酸アルミン酸マグネシウム 15mg
カルボキシメチルセルロースカルシウム 5mg
ヒドロキシプロピルセルロース 2mg
ステアリン酸マグネシウム 1mg
計 92mg
マンニトールをベースにし、表1の処方により直接打錠法によって1錠中プラバスタンNa5mgを含む錠剤を製造し、硬度、崩壊時間、溶出率を測定した。
プラバスタチンNa 5mg
マンニトール 75mg
微結晶セルロース 10mg
ステアリン酸Mg 1mg
合計 91mg
乳糖をベースにし、表3の処方により直接打錠法によって1錠中プラスバスタチンNa5mgを含む錠剤を製造し、実施例2と同様な測定を行った。
1.溶出試験法:JP13第2法
試験液:37℃の水900mL
回転数:50rpm
測定数:N=3
2.崩壊試験法:JP13
測定数:N=6
Claims (4)
- リン酸水素カルシウムまたはメタケイ酸アルミン酸マグネシウムを含有することを特徴とする安定性にすぐれたプラバスタチンナトリウム錠剤。
- リン酸水素カルシウムまたはメタケイ酸アルミン酸マグネシウムに加え、さらに乳糖、崩壊剤および滑沢剤を含有し、直接打錠することによって得たことを特徴とする請求項1に記載のプラバスタチンナトリウム錠剤。
- リン酸水素カルシウムまたはメタケイ酸アルミン酸マグネシウムを配合することを特徴とする錠剤中のプラバスタチンナトリウムを安定化させる方法。
- メタケイ酸アルミン酸マグネシウムを配合することを特徴とする請求項3に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003303781A JP3719679B2 (ja) | 1998-12-07 | 2003-08-28 | プラバスタチンナトリウム錠 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP36608398 | 1998-12-07 | ||
JP2003303781A JP3719679B2 (ja) | 1998-12-07 | 2003-08-28 | プラバスタチンナトリウム錠 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11117389A Division JP2000229855A (ja) | 1998-12-07 | 1999-04-26 | プラバスタチンナトリウム錠 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004002473A true JP2004002473A (ja) | 2004-01-08 |
JP2004002473A5 JP2004002473A5 (ja) | 2005-08-25 |
JP3719679B2 JP3719679B2 (ja) | 2005-11-24 |
Family
ID=30445584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003303781A Expired - Fee Related JP3719679B2 (ja) | 1998-12-07 | 2003-08-28 | プラバスタチンナトリウム錠 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3719679B2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012002464A1 (ja) | 2010-06-30 | 2012-01-05 | 持田製薬株式会社 | ω3脂肪酸の配合製剤 |
WO2012056509A1 (ja) * | 2010-10-25 | 2012-05-03 | 興和株式会社 | 医薬組成物 |
JP4981194B2 (ja) * | 2010-10-25 | 2012-07-18 | 興和株式会社 | 医薬組成物 |
EP2698159A1 (en) * | 2011-04-12 | 2014-02-19 | Sawai Pharmaceutical Co., Ltd. | Pitavastatin-containing preparation and method for producing same |
-
2003
- 2003-08-28 JP JP2003303781A patent/JP3719679B2/ja not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012002464A1 (ja) | 2010-06-30 | 2012-01-05 | 持田製薬株式会社 | ω3脂肪酸の配合製剤 |
US8609138B2 (en) | 2010-06-30 | 2013-12-17 | Mochida Pharmaceutical Co., Ltd. | ω3 fatty acid compound preparation |
EP2664328B1 (en) | 2010-06-30 | 2018-11-21 | Mochida Pharmaceutical Co., Ltd. | Omega3 fatty acid compound preparation |
WO2012056509A1 (ja) * | 2010-10-25 | 2012-05-03 | 興和株式会社 | 医薬組成物 |
WO2012057103A1 (ja) * | 2010-10-25 | 2012-05-03 | 興和株式会社 | 医薬組成物 |
JP4981194B2 (ja) * | 2010-10-25 | 2012-07-18 | 興和株式会社 | 医薬組成物 |
EP2698159A1 (en) * | 2011-04-12 | 2014-02-19 | Sawai Pharmaceutical Co., Ltd. | Pitavastatin-containing preparation and method for producing same |
EP2698159A4 (en) * | 2011-04-12 | 2014-11-05 | Sawai Seiyaku Kk | PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF |
Also Published As
Publication number | Publication date |
---|---|
JP3719679B2 (ja) | 2005-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070036850A1 (en) | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound | |
AU4373300A (en) | Flash-melt oral dose formulations | |
JP2007314578A (ja) | 経口投与後のトリメタジジンの持続性放出を可能とするマトリックス錠 | |
CA2662265A1 (en) | Imatinib compositions | |
JP5344289B2 (ja) | 漢方エキス含有錠剤組成物 | |
CN1819820A (zh) | 包含左甲状腺素钠的药物制剂 | |
JP2000229855A (ja) | プラバスタチンナトリウム錠 | |
JP2007161706A (ja) | 安中散含有錠剤 | |
JP3719679B2 (ja) | プラバスタチンナトリウム錠 | |
JP2000001428A (ja) | 錠剤及び製造法 | |
CN115400128B (zh) | 含盐酸去氧肾上腺素片剂、制备方法及应用 | |
JP2001233766A (ja) | プラバスタチンナトリウムの錠剤 | |
JP4871258B2 (ja) | トラセミドとマトリックス形成ポリマーとを含む持続放出型組成物(prolonged−release composition) | |
JP3687025B2 (ja) | 安定なマレイン酸エナラプリル錠剤 | |
JP5644167B2 (ja) | 溶出改善されたケトチフェン又はその塩を含有する固形製剤 | |
JP5113476B2 (ja) | 保存安定性に優れた塩酸テモカプリルの錠剤 | |
KR100590622B1 (ko) | 레보시멘단과 알긴산을 포함하는 안정한 조성물 | |
JPH1121236A (ja) | ロキソプロフェン・ナトリウム固形製剤 | |
JP2004043509A (ja) | プラバスタチンナトリウム錠の貯蔵安定化方法 | |
JP5490691B2 (ja) | 炭酸カルシウム含有速崩壊性製剤 | |
JP2003073270A (ja) | 安定性および溶出性の良好なプラバスタチンナトリウム錠 | |
JP2005187464A (ja) | 固形製剤およびその製造方法 | |
WO2003086387A1 (en) | Stable tablets comprising simvastatin | |
JP6638947B1 (ja) | 保存安定性に優れたレボセチリジン医薬組成物 | |
JP6037687B2 (ja) | グリメピリドを含有する口腔内崩壊錠 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Effective date: 20050407 Free format text: JAPANESE INTERMEDIATE CODE: A711 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050420 |
|
A621 | Written request for application examination |
Effective date: 20050420 Free format text: JAPANESE INTERMEDIATE CODE: A621 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Effective date: 20050420 Free format text: JAPANESE INTERMEDIATE CODE: A871 |
|
A521 | Written amendment |
Effective date: 20050408 Free format text: JAPANESE INTERMEDIATE CODE: A821 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20050602 |
|
A131 | Notification of reasons for refusal |
Effective date: 20050613 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050809 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050902 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050902 |
|
R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080916 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 3 Free format text: PAYMENT UNTIL: 20080916 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 4 Free format text: PAYMENT UNTIL: 20090916 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 4 Free format text: PAYMENT UNTIL: 20090916 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 5 Free format text: PAYMENT UNTIL: 20100916 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 5 Free format text: PAYMENT UNTIL: 20100916 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100916 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110916 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 6 Free format text: PAYMENT UNTIL: 20110916 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120916 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120916 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120916 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 7 Free format text: PAYMENT UNTIL: 20120916 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 8 Free format text: PAYMENT UNTIL: 20130916 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 8 Free format text: PAYMENT UNTIL: 20130916 |
|
LAPS | Cancellation because of no payment of annual fees |